360 related articles for article (PubMed ID: 34651577)
21. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.
Ssentongo P; Ssentongo AE; Voleti N; Groff D; Sun A; Ba DM; Nunez J; Parent LJ; Chinchilli VM; Paules CI
BMC Infect Dis; 2022 May; 22(1):439. PubMed ID: 35525973
[TBL] [Abstract][Full Text] [Related]
22. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
Barchuk A; Cherkashin M; Bulina A; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Med; 2022 Sep; 20(1):312. PubMed ID: 36123681
[TBL] [Abstract][Full Text] [Related]
23. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.
Fabiani M; Puopolo M; Filia A; Sacco C; Mateo-Urdiales A; Spila Alegiani S; Del Manso M; D'Ancona F; Vescio F; Bressi M; Petrone D; Spuri M; Rota MC; Massari M; Da Cas R; Morciano C; Stefanelli P; Bella A; Tallon M; Proietti V; Siddu A; Battilomo S; Palamara AT; Popoli P; Brusaferro S; Rezza G; Riccardo F; Menniti Ippolito F; Pezzotti P
Expert Rev Vaccines; 2022 Jul; 21(7):975-982. PubMed ID: 35389748
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
26. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
Mazagatos C; Delgado-Sanz C; Monge S; Pozo F; Oliva J; Sandonis V; Gandarillas A; Quiñones-Rubio C; Ruiz-Sopeña C; Gallardo-García V; Basile L; Barranco-Boada MI; Hidalgo-Pardo O; Vazquez-Cancela O; García-Vázquez M; Fernández-Sierra A; Milagro-Beamonte A; Ordobás M; Martínez-Ochoa E; Fernández-Arribas S; Lorusso N; Martínez A; García-Fulgueiras A; Sastre-Palou B; Losada-Castillo I; Martínez-Cuenca S; Rodríguez-Del Águila M; Latorre M; Larrauri A;
Influenza Other Respir Viruses; 2022 Nov; 16(6):1014-1025. PubMed ID: 35880469
[TBL] [Abstract][Full Text] [Related]
29. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.
Hoeve CE; de Gier B; Huiberts AJ; de Melker HE; Hahné SJM; van den Hof S; Knol MJ
J Infect Dis; 2023 Aug; 228(4):431-438. PubMed ID: 37093964
[TBL] [Abstract][Full Text] [Related]
30. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
31. Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.
Aoshima M; Ohfuji S
Hum Vaccin Immunother; 2022 Dec; 18(7):2147353. PubMed ID: 36459056
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.
Menegale F; Manica M; Zardini A; Guzzetta G; Marziano V; d'Andrea V; Trentini F; Ajelli M; Poletti P; Merler S
JAMA Netw Open; 2023 May; 6(5):e2310650. PubMed ID: 37133863
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies.
Pormohammad A; Zarei M; Ghorbani S; Mohammadi M; Aghayari Sheikh Neshin S; Khatami A; Turner DL; Djalalinia S; Mousavi SA; Mardani-Fard HA; Kasaeian A; Turner RJ
Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062684
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
Zheng C; Shao W; Chen X; Zhang B; Wang G; Zhang W
Int J Infect Dis; 2022 Jan; 114():252-260. PubMed ID: 34800687
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022.
Veneti L; Berild JD; Watle SV; Starrfelt J; Greve-Isdahl M; Langlete P; Bøås H; Bragstad K; Hungnes O; Meijerink H
Int J Infect Dis; 2023 May; 130():182-188. PubMed ID: 36893942
[TBL] [Abstract][Full Text] [Related]
37. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
38. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
39. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
40. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
Plumb ID; Fette LM; Tjaden AH; Feldstein L; Saydah S; Ahmed A; Link-Gelles R; Wierzba TF; Berry AA; Friedman-Klabanoff D; Larsen MP; Runyon MS; Ward LM; Santos RP; Ward J; Weintraub WS; Edelstein S; Uschner D
Vaccine; 2023 Apr; 41(15):2596-2604. PubMed ID: 36932031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
